Bookbuilding IPO | ₹409 Cr | Listed at BSE, NSE | Tue, Mar 24, 2026 - Fri, Mar 27, 2026
Sai Parenteral's IPO is a book build issue of ₹408.79 crores. The issue is a combination of fresh issue of 0.73 crore shares aggregating to ₹285.00 crores and offer for sale of 0.32 crore shares aggregating to ₹123.79 crores.
Sai Parenteral's IPO bidding started from Mar 24, 2026 and ended on Mar 27, 2026. The allotment for Sai Parenteral's IPO was finalized on Mar 30, 2026. The shares got listed on the NSE and the BSE on Apr 2, 2026.
Sai Parenteral's IPO is set final issue price at ₹392 per share. The lot size for an application is 38 shares. The minimum amount of investment required by an individual investor (retail) is ₹14,896 (38 shares) (based on upper price). The lot size investment for sNII is 14 lots (532 shares), amounting to ₹2,08,544, and for bNII, it is 68 lots (2,584 shares), amounting to ₹10,12,928.
Arihant Capital Markets Ltd. is the book running lead manager and Bigshare Services Pvt.Ltd. is the registrar of the issue.
Refer to Sai Parenteral's IPO RHP for detailed Information.
IPO Open
Tue, Mar 24, 2026
IPO Close
Fri, Mar 27, 2026
Issue Price
₹392 per share
Market Cap (Pre-IPO)
₹1,731.83 Cr
| IPO Date | 24 to 27 Mar, 2026 |
| Listed on | Thu, Apr 2, 2026 |
| Face Value | ₹5 per share |
| Price Band | ₹372 to ₹392 |
| Issue Price | ₹392 per share |
| Lot Size | 38 Shares |
| Sale Type | Fresh capital cum OFS |
| Issue Type | Bookbuilding IPO |
| Listing At | BSE, NSE |
| Total Issue Size | 1,04,28,288 shares (agg. up to ₹409 Cr) |
| Fresh Issue | 72,70,408 shares (agg. up to ₹285 Cr) |
| Offer for Sale | 31,57,880 shares of ₹5 (agg. up to ₹124 Cr) |
| Share Holding Pre Issue | 3,69,08,823 shares |
| Share Holding Post Issue | 4,41,79,231 shares |
| BSE Script Code / NSE Symbol | 544742 / SAIPARENT |
| ISIN | INE0H9F01037 |
Sai Parenteral's IPO comprises a total issue size of 1,04,28,288 shares. Out of which, 52,14,143 (50.00%) are allocated to QIB, 15,64,244 (15.00%) allocated to NII 36,49,901 (35.00%) allocated to RII.
| Investor Category | Shares Offered | % of Total Issue | Max Allottees |
|---|---|---|---|
| QIB Shares Offered | 52,14,143 | 50.00% | NA |
| − Anchor Investor Shares Offered | 31,28,485 | 30.00% | NA |
| − QIB (Ex. Anchor) Shares Offered | 20,85,658 | 20.00% | NA |
| NII (HNI) Shares Offered | 15,64,244 | 15.00% | NA |
| − bNII > ₹10L | 10,42,829 | 10.00% | 1,960 |
| − sNII < ₹10L | 5,21,415 | 5.00% | 980 |
| Retail Shares Offered | 36,49,901 | 35.00% | 96,050 |
| Total Shares Offered | 1,04,28,288 | 100.00% |
Investors can bid for a minimum of 38 shares and in multiples thereof.
| Application | Lots | Shares | Amount |
|---|---|---|---|
| Retail (Min) | 1 | 38 | ₹14,896 |
| Retail (Max) | 13 | 494 | ₹1,93,648 |
| S-HNI (Min) | 14 | 532 | ₹2,08,544 |
| S-HNI (Max) | 67 | 2,546 | ₹9,98,032 |
| B-HNI (Min) | 68 | 2,584 | ₹10,12,928 |
Sai Parenteral's IPO raises ₹122.64 crore from anchor investors. Sai Parenteral's IPO Anchor bid date is March 23, 2026.
📝 Anchor Investors Letter (PDF)
| Bid Date | Mon, Mar 23, 2026 |
| Shares Offered | 31,28,485 |
| Anchor Portion (₹ Cr.) | 122.64 |
| Anchor lock-in period end date for 50% shares (30 Days) | Tue, Apr 28, 2026 |
| Anchor lock-in period end date for remaining shares (90 Days) | Sat, Jun 27, 2026 |
Incorporated in 2001, Sai Parenteral's Ltd. is a diversified pharmaceutical formulations company with expertise in research, development, and manufacturing.
The company operates in two segments: Branded Generic Formulations and Contract Development and Manufacturing Organisation (CDMO) products and services for domestic and international markets.
The product portfolio spans multiple therapeutic areas including cardiovascular, neuropsychiatry, anti-diabetic, respiratory health, antibiotics, gastroenterology, vitamins, minerals and supplements (VMS), analgesics, and dermatology. Offerings are across dosage forms such as injectables, tablets, capsules, liquid orals, and ointments.
Sai Parenteral's serves a wide customer base comprising central and state government agencies, pharmaceutical companies, public and private hospitals, and super stockists in India. The company entered exports in FY 2023 after acquiring two internationally accredited facilities in Hyderabad, Telangana, and now supplies to regulated and semi-regulated markets in Australia, New Zealand, Southeast Asia, the Middle East, and Africa.
The company owns and operates five manufacturing facilities in India. Four are located in Hyderabad, Telangana, comprising a GMP-compliant injectable unit, a WHO-GMP injectable unit, a TGA-Australia and PIC/S accredited solid oral dosage unit, and a WHO-GMP cephalosporin facility. Its wholly owned subsidiary, Revat Laboratories, operates a GMP-certified facility in Ongole, Andhra Pradesh.
As of December 31, 2025, Sai Parenteral Ltd. employed 298 full-time employees.
Competitive Strength:
| Period Ended | 30 Sep 2025 | 31 Mar 2025 | 31 Mar 2024 | 31 Mar 2023 |
|---|---|---|---|---|
| Assets | 376.24 | 272.39 | 268.10 | 133.96 |
| Total Income | 89.43 | 163.74 | 155.18 | 97.03 |
| Profit After Tax | 7.76 | 14.43 | 8.42 | 4.38 |
| EBITDA | 16.24 | 39.44 | 31.70 | 17.64 |
| NET Worth | 209.37 | 95.78 | 76.40 | 31.49 |
| Reserves and Surplus | 188.84 | 80.36 | 61.30 | 24.34 |
| Total Borrowing | 76.07 | 93.95 | 118.79 | 68.55 |
| Amount in ₹ Crore | ||||
The Company proposes to utilise the Net Proceeds from the Issue towards the following objects:
| # | Issue Objects | Est Amt (₹ Cr.) |
|---|---|---|
| 1 | Capacity expansion and upgradation of manufacturing facilities | 110.80 |
| 2 | Establishment of a new R&D Centre; | 18.02 |
| 3 | Repayment / prepayment of certain outstanding borrowings | 14.30 |
| 4 | Working capital requirements | 33.00 |
| 5 | Investment in wholly owned subsidiary, Sai Parenterals Pte Limited (Singapore), in relation to the proposed acquisition of Noumed Pharmaceuticals Pty Limited (Australia); and | 35.64 |
| 6 | General corporate purposes | 44.74 |
| Total | 256.50 |
| KPI | Sep 30, 2025 | Mar 31, 2025 |
|---|---|---|
| ROE | 5.13% | 16.82% |
| ROCE | 9.28% | 28.92% |
| RoNW | 5.09% | 15.09% |
| PAT Margin | 8.93% | 8.88% |
| EBITDA Margin | 18.68% | 24.18% |
| Price to Book Value | 10.89 |
| Pre IPO | Post IPO | |
|---|---|---|
| EPS (₹) | 5.43 | |
| P/E (x) | 72.19 | |
| Promoter Holding | 61.23% | 51.2% |
| Market Cap | ₹1,731.83 Cr. |
The Sai Parenteral's IPO is subscribed 1.08 times on March 27, 2026 6:54:37 PM (Day 3). The public issue subscribed 0.12 times in the retail category, 1.73 times in the QIB category, and 2.45 times in the NII category. Check Day by Day Subscription Details (Live Status)
| Category | Subscription (x) | Shares Offered | Shares bid for |
|---|---|---|---|
| QIB (Ex Anchor) | 1.73 | 20,85,659 | 36,10,266 |
| NII | 2.45 | 15,64,243 | 38,31,502 |
| bNII (> ₹10L) | 3.56 | 10,42,829 | 37,07,318 |
| sNII (< ₹10L) | 0.24 | 5,21,414 | 1,24,184 |
| Retail | 0.12 | 36,49,901 | 4,39,204 |
| Total | 1.08 | 72,99,803 | 78,80,972 |
Total Applications: 7,938
| # | Issue Expenses | Est Amt (₹ Cr.) |
|---|---|---|
| 1 | Fees payable to the Book Running Lead Manager and commissions (including underwriting commission, brokerage and selling commission) | 14.53 |
| 2 | Commission and processing fees for SCSBs (1)(2) and Bidding Charges for Members of the Syndicate, Registered Brokers, RTAs and CDPs | 7.28 |
| 3 | Fees payable to the Registrar to the Offer | 0.06 |
| 4 | Other expenses | 2.97 |
| 5 | Listing fees, SEBI, BSE and NSE processing fees, book building software fees and other regulatory expenses | 2.29 |
| 6 | Printing and stationery expense | 0.75 |
| 7 | Fees payable to the Statutory Auditor, industry service provider and independent chartered engineer | 4.43 |
| 8 | Advertising and marketing expenses for the Offer | 2.30 |
| 9 | Fees payable to the legal counsels to the Offer | 1.41 |
| 10 | Miscellaneous | 4.82 |
| Total | 40.84 |
| Price Details | BSE | NSE |
|---|---|---|
| Final Issue Price | ₹392.00 | ₹392.00 |
| Open | ₹405.00 | ₹400.00 |
| Low | ₹400.00 | ₹400.00 |
| High | ₹416.20 | ₹416.00 |
| Last Trade | ₹406.40 | ₹405.70 |
Lead Manager Reports
Sai Parenteral's IPO is a main-board IPO of 1,04,28,288 equity shares of the face value of ₹5 aggregating up to ₹409 Crores. The issue is priced at ₹392 per share. The minimum order quantity is 38.
The IPO opens on Tue, Mar 24, 2026, and closes on Fri, Mar 27, 2026.
Bigshare Services Pvt.Ltd. is the registrar for the IPO. The shares are proposed to be listed on BSE, NSE.
Zerodha customers can apply online in Sai Parenteral's IPO using UPI as a payment gateway. Zerodha customers can apply in Sai Parenteral's IPO by login into Zerodha Console (back office) and submitting an IPO application form.
Steps to apply in Sai Parenteral's IPO through Zerodha
Visit Zerodha IPO Application Process Review for more detail.
The Sai Parenteral's IPO opens on Tue, Mar 24, 2026 and closes on Fri, Mar 27, 2026.
Sai Parenteral's IPO lot size is 38, and the minimum amount required for application is ₹14,896.
You can apply in Sai Parenteral's IPO online using either UPI or ASBA as a payment method. ASBA IPO application is available in the net banking of your bank account. UPI IPO Application is offered by brokers who don't offer banking services. Read more detail about applying IPO online through Zerodha, Upstox, 5Paisa, Nuvama, HDFC Bank, and SBI Bank.
The finalization of Basis of Allotment for Sai Parenteral's IPO will be done on Monday, March 30, 2026, and the allotted shares will be credited to your demat account by Wed, Apr 1, 2026. Check the Sai Parenteral's IPO allotment status.
The Sai Parenteral's IPO listing date is on Thu, Apr 2, 2026.
